<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04137822</url>
  </required_header>
  <id_info>
    <org_study_id>2019-IMM101IMM-EU</org_study_id>
    <nct_id>NCT04137822</nct_id>
  </id_info>
  <brief_title>Expanded Access Program Using IMM-101 for Patients With Advanced Pancreatic Cancer</brief_title>
  <official_title>Expanded Access Program Using IMM-101 for Patients With Advanced Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Impatients N.V. trading as myTomorrows</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Immodulon Therapeutics Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Impatients N.V. trading as myTomorrows</source>
  <brief_summary>
    <textblock>
      An Expanded Access Program for IMM-101 for patients with advanced pancreatic cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      IMM-101 is a suspension of heat-killed whole cell Mycobacterium obuense. Since it is a
      heat-killed preparation, treatment is not associated with the potential side-effects of
      delivering live or attenuated organisms.

      Five studies with IMM-101 have been completed including a 110-patient randomised Phase II
      study in pancreatic cancer and exploratory studies in other solid tumours (melanoma,
      colorectal cancer and advanced melanoma).
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <condition>Pancreas Cancer</condition>
  <condition>Pancreatic Cancer</condition>
  <condition>Pancreatic Cancer Stage IV</condition>
  <condition>Pancreatic Cancer Stage III</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IMM-101</intervention_name>
    <description>IMM-101 10mg/mL, a suspension of heat-killed whole cell M. obuense in borate-buffered saline. The treatment regimen with IMM-101 is one dose given every 2 weeks for three doses followed by 4 weeks rest, then one dose is given every 2 weeks for a further three doses. Subsequent doses are given every 4 weeks.</description>
    <other_name>Heat-killed whole cell M. obuense</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        This Expanded Access Program is available for patients of 18 years or older with advanced
        pancreatic cancer for whom, in the opinion of their treating physician, other treatment
        options or clinical trials in this indication are unsuitable.

        Exclusion Criteria:

        Female patient of child-bearing potential who is not, in the opinion of the physician,
        using an approved method of birth control (e.g., physical barrier [patient and partner],
        contraceptive pill or patch, spermicide and barrier, or intrauterine device [IUD]).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Michel van Harten, MD</last_name>
    <phone>+31 885253888</phone>
    <email>medical@mytomorrows.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>France</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>UK</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Costa Neves M, Giakoustidis A, Stamp G, Gaya A, Mudan S. Extended Survival after Complete Pathological Response in Metastatic Pancreatic Ductal Adenocarcinoma Following Induction Chemotherapy, Chemoradiotherapy, and a Novel Immunotherapy Agent, IMM-101. Cureus. 2015 Dec 26;7(12):e435. doi: 10.7759/cureus.435.</citation>
    <PMID>26870619</PMID>
  </reference>
  <results_reference>
    <citation>Dalgleish AG, Stebbing J, Adamson DJ, Arif SS, Bidoli P, Chang D, Cheeseman S, Diaz-Beveridge R, Fernandez-Martos C, Glynne-Jones R, Granetto C, Massuti B, McAdam K, McDermott R, Mart√≠n AJ, Papamichael D, Pazo-Cid R, Vieitez JM, Zaniboni A, Carroll KJ, Wagle S, Gaya A, Mudan SS. Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer. Br J Cancer. 2016 Oct 25;115(9):e16. doi: 10.1038/bjc.2016.342. Epub 2016 Oct 11.</citation>
    <PMID>27727233</PMID>
  </results_reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 22, 2019</study_first_submitted>
  <study_first_submitted_qc>October 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2019</study_first_posted>
  <last_update_submitted>October 22, 2019</last_update_submitted>
  <last_update_submitted_qc>October 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

